ES2759729T3 - Modelo animal para ojo seco y métodos de uso de dichos animales - Google Patents
Modelo animal para ojo seco y métodos de uso de dichos animales Download PDFInfo
- Publication number
- ES2759729T3 ES2759729T3 ES15816590T ES15816590T ES2759729T3 ES 2759729 T3 ES2759729 T3 ES 2759729T3 ES 15816590 T ES15816590 T ES 15816590T ES 15816590 T ES15816590 T ES 15816590T ES 2759729 T3 ES2759729 T3 ES 2759729T3
- Authority
- ES
- Spain
- Prior art keywords
- scopolamine
- administered
- benzalkonium chloride
- candidate agent
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 44
- 206010013774 Dry eye Diseases 0.000 title claims description 77
- 241001465754 Metazoa Species 0.000 title claims description 56
- 238000010171 animal model Methods 0.000 title description 6
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 102
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 102
- 229960002646 scopolamine Drugs 0.000 claims abstract description 59
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims abstract description 57
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims abstract description 57
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims abstract description 57
- 241000283984 Rodentia Species 0.000 claims abstract description 39
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims abstract 17
- 239000003795 chemical substances by application Substances 0.000 claims description 101
- 238000011282 treatment Methods 0.000 claims description 40
- 230000004489 tear production Effects 0.000 claims description 25
- 238000010186 staining Methods 0.000 claims description 23
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 18
- 206010015946 Eye irritation Diseases 0.000 claims description 17
- 231100000013 eye irritation Toxicity 0.000 claims description 17
- 238000002513 implantation Methods 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 12
- 210000004969 inflammatory cell Anatomy 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 206010023642 Lacrimation decreased Diseases 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 230000035168 lymphangiogenesis Effects 0.000 claims description 9
- 230000003204 osmotic effect Effects 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 238000007910 systemic administration Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 238000011740 C57BL/6 mouse Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 51
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 42
- STECJAGHUSJQJN-VJQRDGCPSA-N chembl3084722 Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-VJQRDGCPSA-N 0.000 description 42
- 238000012360 testing method Methods 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 19
- 230000006698 induction Effects 0.000 description 17
- 210000004561 lacrimal apparatus Anatomy 0.000 description 11
- 210000004087 cornea Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 208000021386 Sjogren Syndrome Diseases 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000001365 lymphatic vessel Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 201000000159 corneal neovascularization Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 108010063738 Interleukins Proteins 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000000812 cholinergic antagonist Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002085 irritant Substances 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 4
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 4
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 108050003409 Mediator of RNA polymerase II transcription subunit 22 Proteins 0.000 description 3
- 102100030223 Mediator of RNA polymerase II transcription subunit 22 Human genes 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- WTRRIQCGCGCMQA-CBZIJGRNSA-N 3-Hydroxyestra-1,3,5(10),6-tetraen-17-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 WTRRIQCGCGCMQA-CBZIJGRNSA-N 0.000 description 1
- DVJXNXPFYJIACK-ULQDDVLXSA-N 3-[(5s,8s,11s)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid Chemical compound O1CC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)C2=CC([N+]([O-])=O)=CC=C21 DVJXNXPFYJIACK-ULQDDVLXSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010016260 Fatty acid deficiency Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000799554 Homo sapiens Protein AATF Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- -1 ZONE-QUICK Chemical compound 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 229940059659 erythromycin ophthalmic ointment Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000056845 human AATF Human genes 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000011133 mesenchymal stem cell therapy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
- G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biodiversity & Conservation Biology (AREA)
- Mathematical Analysis (AREA)
- Business, Economics & Management (AREA)
- Algebra (AREA)
- Medical Informatics (AREA)
- Mathematical Optimization (AREA)
- Mathematical Physics (AREA)
- Pure & Applied Mathematics (AREA)
- Computational Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086263P | 2014-12-02 | 2014-12-02 | |
| PCT/US2015/063084 WO2016089807A1 (en) | 2014-12-02 | 2015-12-01 | Animal model for dry eye and methods of use of such animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2759729T3 true ES2759729T3 (es) | 2020-05-12 |
Family
ID=55024246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15816590T Active ES2759729T3 (es) | 2014-12-02 | 2015-12-01 | Modelo animal para ojo seco y métodos de uso de dichos animales |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170360013A1 (https=) |
| EP (1) | EP3226853B1 (https=) |
| JP (1) | JP6692808B2 (https=) |
| KR (1) | KR20170100483A (https=) |
| CN (1) | CN107106553A (https=) |
| AU (1) | AU2015355169A1 (https=) |
| CA (1) | CA2967432A1 (https=) |
| ES (1) | ES2759729T3 (https=) |
| IL (1) | IL252077A0 (https=) |
| MX (1) | MX2017007295A (https=) |
| RU (1) | RU2706787C2 (https=) |
| SG (1) | SG11201703572SA (https=) |
| WO (1) | WO2016089807A1 (https=) |
| ZA (1) | ZA201703052B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3871682A1 (en) * | 2016-10-14 | 2021-09-01 | i.com Medical GmbH | Method for establishing, restoring, and preserving homeostasis of the ocular surface |
| EP3781175A1 (en) | 2018-04-18 | 2021-02-24 | i.com Medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| KR102429281B1 (ko) * | 2020-05-25 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 안구건조증 치료용 약학적 조성물 |
| CN113519461A (zh) * | 2021-07-06 | 2021-10-22 | 江西中洪博元生物技术有限公司 | 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用 |
| WO2023215261A1 (en) * | 2022-05-02 | 2023-11-09 | Ocular Services On Demand, Llc | Mammalian eye models |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003532629A (ja) * | 1999-09-08 | 2003-11-05 | ワトソン ファーマシューティカルズ， インコーポレイテッド | 第４アンモニウム塩の経皮薬剤放出への使用 |
| US20130190278A1 (en) * | 2010-07-29 | 2013-07-25 | Laboratoires Fournier Sa | Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases |
-
2015
- 2015-12-01 US US15/532,527 patent/US20170360013A1/en not_active Abandoned
- 2015-12-01 SG SG11201703572SA patent/SG11201703572SA/en unknown
- 2015-12-01 CN CN201580065760.3A patent/CN107106553A/zh active Pending
- 2015-12-01 MX MX2017007295A patent/MX2017007295A/es unknown
- 2015-12-01 JP JP2017525337A patent/JP6692808B2/ja not_active Expired - Fee Related
- 2015-12-01 WO PCT/US2015/063084 patent/WO2016089807A1/en not_active Ceased
- 2015-12-01 KR KR1020177012469A patent/KR20170100483A/ko not_active Withdrawn
- 2015-12-01 EP EP15816590.2A patent/EP3226853B1/en active Active
- 2015-12-01 ES ES15816590T patent/ES2759729T3/es active Active
- 2015-12-01 RU RU2017118978A patent/RU2706787C2/ru not_active IP Right Cessation
- 2015-12-01 CA CA2967432A patent/CA2967432A1/en not_active Abandoned
- 2015-12-01 AU AU2015355169A patent/AU2015355169A1/en not_active Abandoned
-
2017
- 2017-05-03 IL IL252077A patent/IL252077A0/en unknown
- 2017-05-03 ZA ZA2017/03052A patent/ZA201703052B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3226853A1 (en) | 2017-10-11 |
| JP2018500546A (ja) | 2018-01-11 |
| IL252077A0 (en) | 2017-07-31 |
| KR20170100483A (ko) | 2017-09-04 |
| MX2017007295A (es) | 2018-03-12 |
| RU2706787C2 (ru) | 2019-11-21 |
| CA2967432A1 (en) | 2016-06-09 |
| US20170360013A1 (en) | 2017-12-21 |
| WO2016089807A1 (en) | 2016-06-09 |
| CN107106553A (zh) | 2017-08-29 |
| RU2017118978A3 (https=) | 2019-06-04 |
| RU2017118978A (ru) | 2019-01-09 |
| ZA201703052B (en) | 2019-03-27 |
| SG11201703572SA (en) | 2017-05-30 |
| EP3226853B1 (en) | 2019-09-04 |
| JP6692808B2 (ja) | 2020-05-13 |
| AU2015355169A1 (en) | 2017-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2759729T3 (es) | Modelo animal para ojo seco y métodos de uso de dichos animales | |
| KR102248804B1 (ko) | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 | |
| Yu et al. | Neurokinin-1 receptor antagonism ameliorates dry eye disease by inhibiting antigen-presenting cell maturation and T helper 17 cell activation | |
| CN114269359A (zh) | 用于制备和使用间充质干细胞来源的分泌蛋白质组的方法 | |
| Sumpter et al. | Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses | |
| JP2011527339A (ja) | 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液 | |
| JP2016527250A (ja) | 毒素系治療用ペプチド及びその医薬組成物の眼科的使用 | |
| Avincsal et al. | Effects of topical intranasal doxycycline treatment in the rat allergic rhinitis model | |
| US20190169247A1 (en) | Retinal capillary regeneration with synthetic protein | |
| Oh et al. | The Link module of human TSG-6 (Link_TSG6) promotes wound healing, suppresses inflammation and improves glandular function in mouse models of Dry Eye Disease | |
| ES2871116T3 (es) | Composición farmacéutica de un AINE y atropina | |
| Neves et al. | MANF delivery improves retinal homeostasis and cell replacement therapies in ageing mice | |
| EP3096777B1 (en) | Goblet cell replacement therapy | |
| US20240226180A1 (en) | Methods and compositions for treating dry eye, tear hyperosmolarity, and other ocular conditions | |
| Jin et al. | Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye | |
| ES3025657T3 (en) | Tsg6 polypeptide fragment for dry eye disease | |
| US20150148350A1 (en) | Drug for preventing/treating ocular disease | |
| Mei et al. | Aminooxy-acetic acid inhibits experimental autoimmune uveitis by modulating the balance between effector and regulatory lymphocyte subsets | |
| KR101794225B1 (ko) | 안지오제닌을 유효성분으로 함유하는 각막 내피의 창상 치료용 약학조성물 | |
| Ramos et al. | Ocular immunopathology | |
| JP5800263B2 (ja) | アレルギー性鼻炎治療剤のスクリーニング方法およびその利用 | |
| KR20220051791A (ko) | Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물 | |
| US20250144153A1 (en) | Methods and compositions for treating dry eye, tear hyperosmolarity-induced pathological changes, and other ocular conditions | |
| Huo et al. | Influence of plasma exchange on transplantation related immune function in patients with liver failure | |
| TWI306770B (en) | Pharmaceutical composition for rescuring learning or memory deficits |